ATYR PHARMA INC (ATYR) Stock Price, Quote, News and Overview
NASDAQ:ATYR - Nasdaq - US0021202025 - Common Stock - Currency: USD
ATYR Quote, Performance and Key Statistics
3.4
+0.32 (+10.39%)
The current stock price of ATYR is 3.4 USD. In the past month the price decreased by -12.14%.
ATYR Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.17 | 378.30B | ||
| AMGN | AMGEN INC | 16.39 | 174.51B | ||
| GILD | GILEAD SCIENCES INC | 25.47 | 146.22B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1683.76 | 125.39B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.5 | 77.34B | ||
| ARGX | ARGENX SE - ADR | 231.21 | 36.10B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 31.66B | ||
| ONC | BEIGENE LTD-ADR | N/A | 26.47B | ||
| BNTX | BIONTECH SE-ADR | N/A | 26.08B | ||
| BIIB | BIOGEN INC | 9.13 | 22.01B | ||
| NTRA | NATERA INC | N/A | 19.02B | ||
| GMAB | GENMAB A/S -SP ADR | 24.89 | 15.34B |
Related stock screener links
About ATYR
Company Profile
aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. The company is headquartered in San Diego, California and currently employs 56 full-time employees. The company went IPO on 2015-05-07. The firm is leveraging intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. Its lead therapeutic candidate is efzofitimod, a biologic immunomodulator in clinical development for the treatment of interstitial lung disease (ILD), a group of immune-mediated disorders that can cause inflammation and fibrosis, or scarring, of the lungs. Efzofitimod is a tRNA synthetase derived therapy that selectively modulates activated myeloid cells through neuropilin-2 (NRP2) to resolve aberrant inflammation without immune suppression and prevent the progression of fibrosis. ATYR0101 is a fusion protein derived from a domain of aspartyl-tRNA synthetase (DARS). ATYR0101 binds directly to latent-transforming growth factor beta-binding protein 1 (LTBP1), which regulates transforming growth factor beta (TGFb). Its ATYR0750 is a fusion protein derived from a domain of alanyl-tRNA synthetase (AARS).
Company Info
ATYR PHARMA INC
10240 Sorrento Valley Road, Suite 300
San Diego CALIFORNIA US
Employees: 56
Company Website: https://www.atyrpharma.com/
Investor Relations: https://investors.atyrpharma.com/
Phone: 18587318389
ATYR PHARMA INC / ATYR FAQ
What is the stock price of ATYR PHARMA INC today?
The current stock price of ATYR is 3.4 USD. The price increased by 10.39% in the last trading session.
What is the ticker symbol for ATYR PHARMA INC stock?
The exchange symbol of ATYR PHARMA INC is ATYR and it is listed on the Nasdaq exchange.
On which exchange is ATYR stock listed?
ATYR stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ATYR PHARMA INC stock?
17 analysts have analysed ATYR and the average price target is 18.76 USD. This implies a price increase of 451.67% is expected in the next year compared to the current price of 3.4. Check the ATYR PHARMA INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ATYR PHARMA INC worth?
ATYR PHARMA INC (ATYR) has a market capitalization of 285.40M USD. This makes ATYR a Micro Cap stock.
How many employees does ATYR PHARMA INC have?
ATYR PHARMA INC (ATYR) currently has 56 employees.
What are the support and resistance levels for ATYR PHARMA INC (ATYR) stock?
ATYR PHARMA INC (ATYR) has a support level at 3.39. Check the full technical report for a detailed analysis of ATYR support and resistance levels.
Is ATYR PHARMA INC (ATYR) expected to grow?
The Revenue of ATYR PHARMA INC (ATYR) is expected to decline by -55.08% in the next year. Check the estimates tab for more information on the ATYR EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy ATYR PHARMA INC (ATYR) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ATYR, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ATYR, evaluating the profitability, health, valuation and growth aspects
- ATYR PHARMA INC (ATYR) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ATYR PHARMA INC (ATYR) Sales and EPS estimates to see what analysts future expectations are.
- ATYR PHARMA INC (ATYR) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ATYR PHARMA INC (ATYR) Insider and Institutional Ownership to learn about the owners and their transactions.
- ATYR PHARMA INC (ATYR) Stock Chart to make your own analysis
- ATYR PHARMA INC (ATYR) Latest news and press-releases to stay up to date.
Does ATYR PHARMA INC (ATYR) stock pay dividends?
ATYR does not pay a dividend.
When does ATYR PHARMA INC (ATYR) report earnings?
ATYR PHARMA INC (ATYR) will report earnings on 2025-03-13, after the market close.
What is the Price/Earnings (PE) ratio of ATYR PHARMA INC (ATYR)?
ATYR PHARMA INC (ATYR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.94).
What is the Short Interest ratio of ATYR PHARMA INC (ATYR) stock?
The outstanding short interest for ATYR PHARMA INC (ATYR) is 5.3% of its float. Check the ownership tab for more information on the ATYR short interest.
ATYR Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to ATYR.
ATYR Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ATYR. ATYR has a bad profitability rating. Also its financial health evaluation is rather negative.
ATYR Financial Highlights
Over the last trailing twelve months ATYR reported a non-GAAP Earnings per Share(EPS) of -0.94. The EPS increased by 3.09% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -69.66% | ||
| ROE | -97.69% | ||
| Debt/Equity | 0.02 |
ATYR Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 84% to ATYR. The Buy consensus is the average rating of analysts ratings from 17 analysts.
For the next year, analysts expect an EPS growth of 3.21% and a revenue growth -55.08% for ATYR